Back to Search
Start Over
Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer
- Source :
- International Journal of Clinical Oncology. 25:1807-1813
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- Background A 4-week administration of tegafur/gimeracil/oteracil (S-1) followed by a 2-week rest is the standard adjuvant chemotherapy for surgically resected advanced gastric cancer. This study aimed to evaluate the oncological feasibility of a 2-week S-1 administration followed by a 1-week rest, which is frequently applied in clinical practice to reduce toxicity and improve drug adherence. Methods We retrospectively enrolled patients with stage II/III gastric cancer who received S-1 adjuvant chemotherapy following radical gastrectomy from 2006 to 2016 in three institutions. Two-week and 4-week regimen cohorts were compared for relative dose intensity (RDI) as a primary outcome, and treatment completion rate, adverse event incidence, overall survival (OS), and relapse-free survival (RFS) as secondary outcomes. Confounders were adjusted for using propensity score matching (PSM). Results One hundred and thirty-four patients received the 2-week regimen and 121 patients received the 4-week regimen. Ninety-five patients were extracted from each group after PSM. The RDIs of S-1 in the 2-week and 4-week cohorts were 73.5 and 69.9%, respectively (p = 0.35), which were not significantly different. The treatment completion rate (54.7 vs. 53.7%, p = 1.0), incidence of grade ≥3 adverse events (7.4 vs. 12.6%, p = 0.33), 3-year OS (76.4 vs. 82.7%, p = 0.78), and 3-year RFS (71.3 vs. 73.4%, p = 0.70) did not significantly differ between both cohorts. Conclusions The 2-week S-1 adjuvant chemotherapy could not improve drug adherence in terms of RDI, but its relapse rates were not significantly different compared with those of the 4-week regimen. The 2-week regimen might be considered as an option depending on the patient’s status.
- Subjects :
- Male
0301 basic medicine
medicine.medical_specialty
Tegafur
03 medical and health sciences
0302 clinical medicine
Gastrectomy
Stomach Neoplasms
Surgical oncology
Internal medicine
Humans
Medicine
Propensity Score
Adverse effect
Aged
Retrospective Studies
business.industry
Incidence (epidemiology)
Cancer
Hematology
General Medicine
Middle Aged
medicine.disease
Drug Combinations
Oxonic Acid
Regimen
Treatment Outcome
030104 developmental biology
Oncology
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Propensity score matching
Toxicity
Female
Surgery
Neoplasm Recurrence, Local
business
medicine.drug
Subjects
Details
- ISSN :
- 14377772 and 13419625
- Volume :
- 25
- Database :
- OpenAIRE
- Journal :
- International Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....c2a212fb01fcee5c240814e8b21abea0